Literature DB >> 17164565

Mortality due to amyotrophic lateral sclerosis and Parkinson's disease among melanoma patients.

P D Baade1, L Fritschi, D M Freedman.   

Abstract

Recent studies in the USA and elsewhere have identified a possible association between Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and melanoma. However, empirical evidence is very limited. We conducted a study of all people diagnosed as having melanoma in Australia since 1982 (n = 127,037). The subjects, excluding those who had died within 12 months of diagnosis, were followed until 31 December 2001. We then compared their mortality risk of ALS and PD to that of the general population. There were a total of 53 ALS deaths and 129 deaths due to PD. Although the absolute risk is small, the melanoma cohort had a risk of death due to ALS 70% higher (standardised mortality ratio = 169.4, 95% CI = 127-221) than the general population, and nearly a 3-fold increased risk of dying from PD (standardised mortality ratio = 266.3, 95% CI = 222-317). These increased risks continued for long-term survivors, arguing against a surveillance effect (particularly for ALS). The consistency of these results in 2 separate populations (Australia and USA) strengthens the evidence for an association between melanoma and each of the 2 neurodegenerative diseases.

Entities:  

Mesh:

Year:  2007        PMID: 17164565     DOI: 10.1159/000097851

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  21 in total

1.  No role for melanoma treatment in the association between melanoma and amyotrophic lateral sclerosis or Parkinson's disease.

Authors:  Peter D Baade; Elena Herrero Hernández; D Michal Freedman; B Mark Smithers; Lin Fritschi
Journal:  Neuroepidemiology       Date:  2010-10-21       Impact factor: 3.282

2.  Metazoan innovation: from aromatic amino acids to extracellular signaling.

Authors:  Katrina M Kutchko; Jessica Siltberg-Liberles
Journal:  Amino Acids       Date:  2013-05-21       Impact factor: 3.520

Review 3.  Meta-analysis of the relationship between Parkinson disease and melanoma.

Authors:  Rui Liu; Xiang Gao; Yi Lu; Honglei Chen
Journal:  Neurology       Date:  2011-06-07       Impact factor: 9.910

4.  Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.

Authors:  Hwa Jin Lee; Brian A Wall; Janet Wangari-Talbot; Seung-Shick Shin; Stephen Rosenberg; Joseph L-K Chan; Jin Namkoong; James S Goydos; Suzie Chen
Journal:  Clin Cancer Res       Date:  2011-08-15       Impact factor: 12.531

5.  The association between cancer and amyotrophic lateral sclerosis.

Authors:  D Michal Freedman; Rochelle E Curtis; Sarah E Daugherty; James J Goedert; Ralph W Kuncl; Margaret A Tucker
Journal:  Cancer Causes Control       Date:  2012-10-23       Impact factor: 2.506

6.  The risk of amyotrophic lateral sclerosis after cancer in U.S. elderly adults: a population-based prospective study.

Authors:  D Michal Freedman; Jincao Wu; Sarah E Daugherty; Ralph W Kuncl; Lindsey R Enewold; Ruth M Pfeiffer
Journal:  Int J Cancer       Date:  2014-02-28       Impact factor: 7.396

Review 7.  G-protein-coupled receptors and melanoma.

Authors:  Hwa Jin Lee; Brian Wall; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2008-05-27       Impact factor: 4.693

Review 8.  The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers.

Authors:  Rivka Inzelberg; Simon D Israeli-Korn
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

9.  The melanocortin 1 receptor (Mc1r) variants do not account for the co-occurrence of Parkinson's disease and malignant melanoma.

Authors:  Sandra Elincx-Benizri; Rivka Inzelberg; Lior Greenbaum; Oren S Cohen; Gilad Yahalom; Yael Laitman; Ruth Djaldetti; Yael Orlev; Alon Scope; Esther Azizi; Eitan Friedman; Sharon Hassin-Baer
Journal:  J Mol Neurosci       Date:  2014-10-05       Impact factor: 3.444

10.  Cancer in Parkinson's disease.

Authors:  Pawel Tacik; Sadie Curry; Shinsuke Fujioka; Audrey Strongosky; Ryan J Uitti; Jay A van Gerpen; Nancy N Diehl; Michael G Heckman; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2016-06-20       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.